Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from NTRA

Natera Buys Foresight To Boost Super-Early Cancer Detection Tech

Natera, Inc. (NASDAQ:NTRA) on Friday acquired Foresight Diagnostics, a cancer diagnostics company, for $275 million upfront with an additional $175 million in earnouts tied to the achievement of revenue- and reimbursement-based milestones.

NeoGenomics Gains 'Unexpected' Win As Court Rejects Natera Claims

NeoGenomics Gains 'Unexpected' Win As Court Rejects Natera Claims

On Friday, the District Court for the Middle District of North Carolina issued a ruling invalidating specific claims in two patents that Natera Inc. (NASDAQ:NTRA) asserted against NeoGenomics, Inc.'s (NASDAQ:NEO) v1.1 RaDaR test.

S&P Futures Tread Water Ahead of Powell Speech, Disney Earnings on Tap

S&P Futures Tread Water Ahead of Powell Speech, Disney Earnings on Tap

December S&P 500 futures (ESZ23) are trending up +0.06% this morning as investors looked ahead to comments from Fed Chair Jerome Powell for further clues on the U.S. central bank’s monetary policy path while also awaiting an earnings report from Disney.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

This Diagnostic Testing Company Down 60% - Time to Buy?

Despite witnessing double-digit revenue growth in the last reported quarter Natera Inc. (NTRA) stock has plunged nearly 60% year-to-date. So, let’s evaluate if it is worth buying the stock now. Read on.

8 Analysts Have This to Say About Natera

Within the last quarter, Natera (NASDAQ:NTRA) has observed the following analyst ratings:

Natera Clocks 28% Jump In Q1 Sales, Lifts FY22 Guidance

Natera Inc (NASDAQ:NTRA) generated Q1 revenues of $194.1 million, up 27.5% Y/Y, beating the consensus of $176.60 million. Product revenues were $190.0 million, an increase of 57.8%. The company processed approximately 489,300 tests, compared to approximately 348,200 tests in Q1 FY21. The gross profit margin compressed to 46.8% from 56.1%, primarily due…

$100 Invested In Natera 5 Years Ago Would Be Worth This Much

Natera (NASDAQ:NTRA) has outperformed the market over the past 5 years by 22.16% on an annualized basis.

inkl

Read news from The Economist, FT, and more,
with one subscription

3 Reasons Why This Natera Analyst Says The Selloff Is Overdone

3 Reasons Why This Natera Analyst Says The Selloff Is Overdone

Natera Inc (NASDAQ: NTRA) analyst Kyle Mikson of Canaccord Genuity Capital reiterated a Buy rating Wednesday on the genetic testing company following a Hindenburg Research short

Analyst Ratings For Natera

Analyst Ratings For Natera

Over the past 3 months, 4 analysts have published their opinion on Natera (NASDAQ:NTRA) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Natera's Debt Overview

Natera's Debt Overview

Over the past three months, shares of Natera (NASDAQ:NTRA) decreased by 34.50%. Before we understand the importance of debt, let us look at how much debt Natera has.

1

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

Warner Bros Discovery

the District Court

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Monetary Policy

Places

397,157 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play